In vitro diagnostics (IVD) is the technique of diagnostic test outside the human body in an artificial environment. The IVD market revenue is expected to reach $74.65 billion by 2020, from the market value of $53.32 billion in 2013, at a CAGR of 5.34% during 2014-2020. The global IVD market is segmented based on techniques, product type, usability, application, end user and geography (North America, Europe, Asia Pacific and Rest of World). Geographically, Asia Pacific is the fastest growing region and very opportune market that would generate highest revenue by 2020.
Increase in the number of chronic and infectious diseases, and technological advancements are the major driving factors for the market. Widespread knowledge of healthcare & its benefits, and cost effectiveness are some top impacting factors of the global IVD market. The stringent regulatory policies and reimbursement issues are limiting the growth of the market. Furthermore, the rising demand for technologically advanced diagnosis devices and increased spending capabilities of consumers on health care provides huge potential for IVD in Asia Pacific market.
IVD Techniques Market Analysis
Global IVD techniques market is been segmented based on immunoassays, clinical chemistry, point of care, molecular diagnostics, hematology, coagulation, microbiology and other clinical techniques. Point of care is the highest revenue-generating segment in the overall IVD techniques market. Molecular diagnostics is the fastest growing technique in the in the overall IVD techniques market due to its ability to detect the primary cause of the disease accurately
IVD Product Type Market Analysis
The product type segment is been segmented based on instruments, reagents, data management systems and services. Instruments hold the highest market share in the global IVD market followed by reagents. Reagents market is also growing at a faster pace. As it is mostly used in various equipment and play a key role in the overall diagnosis process. Rise in the usage of diagnostic devices in which reagents are required for performing diagnosis tests, is the major factor that drives the product type market.
IVD Usability Market Analysis
Usability segment is classified as disposable and reusable IVD devices. Doctors and clinicians currently prefer disposable devices, to avoid infections. Still, reusable IVD device holds the largest revenue share in the global IVD usability market. Cost effectiveness as a benefit of reusable devices is driving the growth of usability market.
IVD Applications Market Analysis
The application area is segmented based on infectious diseases, diabetes, cancer/oncology, cardiology, autoimmune diseases, nephrology, drug testing, HIV/AIDS and others. Infectious diseases generated the highest revenue for current and forecast period mainly due to rise in the incidences of infectious diseases. HIV/AIDS application market is the second largest revenue generating applications segment and would remain the second largest through 2020.
IVD End User Market Analysis
Hospitals, laboratories, academics, point of care testing and others are the end users of global IVD market. Academic institutions provide trainings of IVD to the students. Laboratories generate the highest revenue followed by point of care for global end user market. Rise in the number of laboratories in Asia Pacific regions and increased awareness about health care and its benefits are contributing towards the growth of laboratories market, which in turn drives the global IVD end users market.
IVD Geography Market Analysis
The detailed analysis of the global IVD market is done in various regions such as North America, Europe, Asia Pacific and Rest of World. North America is the largest revenue generating region in all segments of global IVD market, whereas Asia Pacific region is fastest growing region amongst the regions studied.
IVD Competitive Analysis
The study of top ten players in the global market reveals strategies adopted to maintain their position in the competitive market. Strategic analysis of the top players reveals that market players are adopting product launch as their key developmental strategy in the market, as the market players are innovating novel products to expand their product line. Acquisitions and approvals are some additional strategies adopted by the companies in the market to enhance their services and expand their reach across the globe.
IVD High Level Analysis
The market exploration provides a clear view of global IVD market. Porter’s five-force model helps in analyzing market players, new entrants in the market and the novel strategies adopted by them. In the current business scenario, IVD market has moderate bargaining power of supplier due to existence of brand loyalty. Varying product differentiation would lead to moderate buyers’ bargaining. High entry barriers lead to lower threat of new entrants. Intersegment substitution leads to lower threat of Substitute. The value chain analysis reveals the key intermediaries involved in the supply chain. Raw material suppliers, medical device manufacturers, distributors, service providers and end users are the various stakeholders involved in the supply chain of IVD market.
Reason For Study
IVD is the oldest technique for diagnosis of the disease. With increase in incidences of chronic and infectious diseases and rise in healthcare awareness amongst patients, the market is opportunistic in different geographies. As there is a shift from traditional diagnostic devices to advanced diagnostic devices, IVD would prove to be a lucrative market in future.
KEY DELIVERABLES
KEY MARKET SEGMENTS
MARKET BY TECHNIQUES
MARKET BY PRODUCT TYPE
MARKET BY USABILITY
MARKET BY APPLICATIONS
MARKET BY END USER
MARKET BY GEOGRAPHY
CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key market segments
1.3 Research methodology
1.3.1 Secondary research
1.3.2 Primary research
1.3.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top impacting factors for the in vitro diagnostic market
3.2.2 Top investment pockets
3.2.3 Top winning strategies
3.3 Porter five forces model
3.3.1 Brand loyalty leads to moderate bargaining power of supplier
3.3.2 Varying product differentiation would lead to moderate bargaining power of buyers
3.3.3 Low threat from new entrants due to high entry barriers
3.3.4 Less intersegment substitution leads to lower threat Of substitute
3.3.5 Moderate competitive rivalry
3.4 Government regulations
3.5 Value chain analysis
3.6 Case studies
3.6.1 Case Study 1: Positioning of new IVD Platform by Life Science
3.6.2 Case Study 2: To enhance the operational capabilities of diagnostic chemistry system
3.7 Key technology trends
3.7.1 Medical automation technologies
3.7.2 Emerging markets in digital pathology
3.7.3 Omics and IVD
3.7.4 Genetics tests and IVD
3.7.5 Point of care testing:
3.7.6 Personalized medicine propelling growth:
3.7.7 Emerging diagnostic technologies and impact on IVD
3.8 Market dynamics
3.8.1 Drivers
3.8.1.1 Increasing incidences of chronic and infectious diseases
3.8.1.2 Technological advancements in IVD
3.8.1.3 Emergence of minimal invasive technologies
3.8.1.4 Increasing government expenditures on healthcare
3.8.1.5 Increase in popularity personalized medicine approach
3.8.2 Restraints
3.8.2.1 Unclear reimbursement policies
3.8.2.2 Stringent Regulatory policies
3.8.3 Opportunities
3.8.3.1 Potential Opportunities for outsourcing
3.8.3.2 Convergence of new Technologies.
CHAPTER 4 GLOBAL IVD MARKET BY TECHNIQUES
4.1 Immunoassay/Immunochemistry
4.2 Hematology
4.2.1 High throughput analyzer
4.2.2 Medium throughput analyzer
4.2.3 Low throughput analyzer
4.3 Clinical chemistry
4.3.1 Urine chemistry analyzers
4.3.2 Blood gas electrolyte analyzers
4.3.3 Others
4.4 Coagulation
4.5 Microbiology
4.5.1 Blood culture
4.5.2 Pathological culture
4.5.3 Identification & antibiotic susceptibility testing
4.5.4 Others
4.6 Molecular diagnostics
4.6.1 Infectious diseases
4.6.2 Oncology
4.6.3 Genetic diseases
4.6.4 Blood screening
4.6.5 Others
4.7 Point of care
4.8 Other clinical techniques
4.8.1 Clinical centrifuges
4.8.2 Tissue diagnosis
4.8.3 Sample processors
4.8.4 Flow cytometry
4.8.5 Cytology
CHAPTER 5 GLOBAL IVD MARKET BY PRODUCT TYPE
5.1 Instruments
5.2 Reagents
5.3 Data management system hardware/software
5.4 Services
CHAPTER 6 GLOBAL IVD MARKET BY USABILITY
6.1 Disposable IVD devices
6.2 Re-Usable IVD devices
CHAPTER 7 GLOBAL IVD MARKET BY APPLICATION
7.1 Infectious diseases
7.2 Diabetes
7.3 Cancer/Oncology
7.4 Cardiology
7.5 Autoimmune diseases
7.6 Nephrology
7.7 Drug testing
7.8 HIV/AIDS
7.9 Others
CHAPTER 8 GLOBAL IVD MARKET BY END USERS
8.1 Hospitals
8.2 Laboratory
8.3 Academics
8.4 Point-of-Care Testing
8.5 Others
CHAPTER 9 GLOBAL IVD MARKET BY GEOGRAPHY
9.1 North America
9.2 Europe
9.3 Asia Pacific
9.4 RoW
CHAPTER 10 COMPANY PROFILES
10.1 Alere Inc
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Business performance
10.1.4 Key Strategies and developments
10.1.5 SWOT analysis of Alere
10.2 Biomerieux
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Business performance
10.2.4 Key Strategies and developments
10.2.4.1 Primary STRATEGIES: APPROVAL
10.2.4.2 Secondary strategies: Acquisition
10.2.5 SWOT analysis of BioMerieux
10.3 Danaher Corporation.
10.3.1 Company overview
10.3.2 Company snapshot
10.3.3 Business performance
10.3.4 Key Strategies and development
10.3.5 SWOT analysis of Danaher
10.4 Roche Diagnostics.
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Business performance
10.4.4 Key Strategies and developments
10.4.5 SWOT analysis of Roche
10.5 Becton Dickinson And Company
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Business performance
10.5.4 Key Strategies and development
10.5.4.1 Primary strategies: product launch
10.5.4.2 Secondary strategies: Acquisition and Approval
10.5.5 SWOT analysis of Becton Dickinson and Company
10.6 Bio-Rad Laboratories
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Business performance
10.6.4 Key Strategies and developments
10.6.5 SWOT analysis of Bio-Rad Laboratories
10.7 Abbott Laboratories
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Business Performance
10.7.4 Key Strategies and developments
10.7.5 SWOT analysis of Abbott Laboratories
10.8 Bayer AG.
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Business Performance
10.8.4 Key Strategies and Development
10.8.5 SWOT analysis of Bayer AG
10.9 Arkray Inc.
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Key Strategies and development
10.9.3.1 Primary strategies
10.9.3.2 Secondary strategies
10.9.4 SWOT analysis of Arkray
10.10 Sysmex
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Business performance
10.10.4 Key strategies and developments
10.10.4.1 Primary strategies: partnership
10.10.4.2 Secondary strategies: approval
10.10.5 SWOT analysis of Sysmex
10.11 Johnson & Johnson
10.11.1 Company overview
10.11.2 Company snapshot
10.11.3 Business Performance
10.11.4 Key Strategies and Development
10.11.4.1 Primary strategies: partnership
10.11.4.2 Secondary strategies
10.11.5 SWOT analysis of Johnson & Johnson
10.12 Siemens
10.12.1 Company overview
10.12.2 Company snapshot
10.12.3 Business performance
10.12.4 Key Strategies and development
10.12.5 SWOT analysis of Siemens
List of Tables
TABLE 1 IVD MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
TABLE 2 PORTERS FIVE FORCES MODEL
TABLE 3 GLOBAL INCIDENCES OF DISEASES
TABLE 4 GLOBAL IVD MARKET BY TECHNIQUE, 2013-2020 ($BILLION)
TABLE 5 GLOBAL IMMUNOASSAY TECHNIQUE MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
TABLE 6 GLOBAL HEMATOLOGY TECHNIQUE MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
TABLE 7 GLOBAL CLINICAL CHEMISTRY TECHNIQUE MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
TABLE 8 GLOBAL COAGULATION TECHNIQUE MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
TABLE 9 GLOBAL MICROBIOLOGY TECHNIQUE MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
TABLE 10 GLOBAL MOLECULAR DIAGNOSTICS TECHNIQUE MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
TABLE 11 POINT OF CARE TECHNIQUE MARKET,2013-2020,($BILLION)
TABLE 12 GLOBAL OTHER TECHNIQUES MARKET BY GEOGRAPHY, 2013.-.2020, -.($BILLION)
TABLE 13 GLOBAL IVD BY PRODUCT TYPE MARKET, 2013-2020 ($BILLION)
TABLE 14 GLOBAL INSTRUMENTS MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
TABLE 15 GLOBAL REAGENTS MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
TABLE 16 GLOBAL DATA MANAGEMENT SOFTWARE MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
TABLE 17 GLOBAL SERVICES MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
TABLE 18 GLOBAL IVD USABILITY MARKET, 2013-2020 ($BILLION)
TABLE 19 GLOBAL IVD DISPOSABLE DEVICES MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
TABLE 20 GLOBAL IVD REUSABLE DEVICES MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
TABLE 21 LIST OF MANUFACTURERS WITH RE-USABLE IVD DEVICES
TABLE 22 GLOBAL IVD APPLICATIONS MARKET, 2013-2020 ($BILLION)
TABLE 23 GLOBAL IVD INFECTIOUS DISEASES MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
TABLE 24 GLOBAL IVD DIABETES MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
TABLE 25 GLOBAL IVD CANCER/ONCOLOGY MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
TABLE 26 GLOBAL IVD CARDIOLOGY MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
TABLE 27 GLOBAL IVD AUTOIMMUNE DISEASES MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
TABLE 28 GLOBAL IVD NEPHROLOGY MARKET BY GEOGRAPHY, 2013-2020,- ($BILLIONS)
TABLE 29 GLOBAL IVD DRUG TESTING MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
TABLE 30 GLOBAL IVD HIV/AIDS MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
TABLE 31 GLOBAL IVD OTHER DISEASES MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
TABLE 32 GLOBAL IVD MARKET BY END USER ,2013-2020,($BILLION)
TABLE 33 GLOBAL IVD HOSPITALS MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
TABLE 34 GLOBAL IVD LABORATORY MARKET BY GEOGRAPHY,2013-2020,($BILLIONS)
TABLE 35 GLOBAL IVD ACADEMICS MARKET BY GEOGRAPHY, 2013- 2020 ($BILLIONS)
TABLE 36 GLOBAL IVD POINT OF CARE TESTING MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
TABLE 37 GLOBAL IVD OTHER MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
TABLE 38 GLOBAL IVD MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
TABLE 39 GLOBAL IVD NORTH AMERICA MARKET, 2013-2020 ($BILLION)
TABLE 40 GLOBAL IVD EUROPE MARKET, 2013-2020 ($BILLION)
TABLE 41 GLOBAL IVD ASIA PACIFIC MARKET, 2013-2020 ($BILLION)
TABLE 42 GLOBAL IVD REST OF THE WORLD MARKET, 2013-2020 ($BILLION)
TABLE 43 ALERE COMPANY SNAPSHOT
TABLE 44 BIOMERIEUX COMPANY SNAPSHOT
TABLE 45 DANAHER COMPANY SNAPSHOT
TABLE 46 ROCHE COMPANY SNAPSHOT
TABLE 47 BECTON DICKINSON AND COMPANY SNAPSHOT
TABLE 48 BIO-RAD LABORATORIES SNAPSHOT
TABLE 49 ABBOTT LABORATORIES SNAPSHOT
TABLE 50 BAYER AG COMPANY SNAPSHOT
TABLE 51 ARKRAY COMPANY SNAPSHOT
TABLE 52 SYSMEX COMPANY SNAPSHOT
TABLE 53 JOHNSON & JOHNSON COMPANY SNAPSHOT
TABLE 54 SIEMENS COMPANY SNAPSHOT
List of Figures
FIG. 1 TOP IMPACTING FACTORS
FIG. 2 TOP INVESTMENT POCKETS OF IVD MARKET BY TECHNIQUES 2013-2020.
FIG. 3 TOP WINNING STRATEGIES
FIG. 4 TOP WINNING STRATEGIES
FIG. 5 VALUE CHAIN ANALYSIS FOR IVD MARKET
FIG. 6 KEY FINANCIALS OF ALERE BY SALES 2013
FIG. 7 KEY FINANCIALS OF NET REVENUE BY GEOGRAPHY 2013
FIG. 8 SWOT ANALYSIS OF ALERE
FIG. 9 KEY FINANCIALS OF BREAKDOWN OF SALES BY TECHNOLOGY
FIG. 10 KEY FINANCIALS OF BREAKDOWN OF SALES BY GEOGRAPHY
FIG. 11 SWOT ANALYSIS OF BIOMERIEUX
FIG. 12 KEY FINANCIALS OF DANAHER SALES BY SEGMENT 2013
FIG. 13 KEY FINANCIALS OF DANAHER SALES BY GEOGRAPHY 2013
FIG. 14 SWOT ANALYSIS OF DANAHER
FIG. 15 KEY FINANCIALS OF ROCHE REVENUES BY SEGMENT 2012
FIG. 16 KEY FINANCIALS OF ROCHE SALES BY GEOGRAPHY 2013
FIG. 17 SWOT ANALYSIS OF ROCHE
FIG. 18 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY REVENUES BY SEGMENT 2013
FIG. 19 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY SALES BY GEOGRAPHY 2013
FIG. 20 SWOT ANALYSIS OF BECTON DICKINSON AND COMPANY
FIG. 21 KEY FINANCIALS OF BIO-RAD LABORATORIES REVENUES BY SEGMENT 2013
FIG. 22 KEY FINANCIALS OF BIO-RAD LABORATORIES REVENUES BY GEOGRAPHY 2013
FIG. 23 SWOT ANALYSIS OF BIO-RAD LABORATORIES
FIG. 24 KEY FINANCIALS OF ABBOTT LABORATORIES REVENUES BY SEGMENT 2013
FIG. 25 KEY FINANCIALS OF ABBOTT LABORATORIES REVENUES BY GEOGRAPHY 2013
FIG. 26 SWOT ANALYSIS OF ABBOTT LABORATORIES
FIG. 27 KEY FINANCIALS OF BAYER AG COMPANY REVENUES BY SEGMENT 2013
FIG. 28 SWOT ANALYSIS OF BAYER AG
FIG. 29 SWOT ANALYSIS OF ARKRAY
FIG. 30 KEY FINANCIALS OF SYSMEX COMPANY REVENUES BY SEGMENT 2013
FIG. 31 KEY FINANCIALS OF SYSMEX COMPANY REVENUES BY GEOGRAPHY 2013
FIG. 32 SWOT ANALYSIS OF SYSMEX
FIG. 33 KEY FINANCIALS OF JOHNSON & JOHNSON COMPANY REVENUES BY SEGMENT 2013
FIG. 34 KEY FINANCIALS OF JOHNSON & JOHNSON COMPANY REVENUES BY GEOGRAPHY 2013
FIG. 35 SWOT ANALYSIS OF JOHNSON & JOHNSON
FIG. 36 KEY FINANCIALS OF SIEMENS COMPANY REVENUES BY SEGMENT 2013
FIG. 37 KEY FINANCIALS OF SIEMENS COMPANY REVENUES BY GEOGRAPHY 2013
FIG. 38 SWOT ANALYSIS OF SIEMENS
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
